Core Viewpoint - BioLife Solutions, Inc. (BLFS) has received an upgrade to a Zacks Rank 1 (Strong Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling pressure that affects stock prices [4]. Company Performance Indicators - BioLife Solutions is expected to earn $0.05 per share for the fiscal year ending December 2025, with no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for BioLife Solutions has increased by 150%, reflecting a significant positive revision in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of BioLife Solutions to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10].

Group 1 - BioLife Solutions, Inc. (BLFS) shares have increased by 1.6% over the past four weeks, closing at $22.37, with a mean price target of $31.3 indicating a potential upside of 39.9% [1] - The average of 10 short-term price targets ranges from $30.00 to $34.00, with a standard deviation of $1.42, suggesting a potential increase of 34.1% to 52% from the current price level [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases, as indicated by a 150% increase in the Zacks Consensus Estimate for the current year [11][12] Group 2 - BLFS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While consensus price targets may not be reliable for predicting exact price movements, they can provide a directional guide for potential stock performance [14]

Financial Performance - BioLife Solutions, Inc. (BLFS) reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.02, and improved from a loss of $0.06 per share a year ago, representing an earnings surprise of +100.00% [1] - The company posted revenues of $25.42 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 6.98%, although this is a decline from year-ago revenues of $28.33 million [2] - Over the last four quarters, BioLife Solutions has consistently surpassed consensus EPS and revenue estimates [2] Stock Performance and Outlook - BioLife Solutions shares have declined approximately 18.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $24.55 million, and for the current fiscal year, it is $0.02 on revenues of $97.83 million [7] Industry Context - The Medical - Products industry, to which BioLife Solutions belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5]

Financial Data and Key Metrics Changes - In Q2 2025, total revenue increased by 29% year over year to $25.4 million, driven by a 28% increase in cell processing revenue [16][6] - Adjusted EBITDA margin expanded by 400 basis points to 24%, reflecting strong operating leverage [6] - GAAP net loss was $15.8 million or $0.33 per share, compared to a net loss of $5.6 million or $0.12 per share in the prior year [20][16] Business Line Data and Key Metrics Changes - Cell processing revenue reached $23 million, marking a 28% year-over-year increase and a 6% sequential increase [8] - Biopreservation media (BPM) products accounted for approximately 85% of Q2 cell processing revenue, with top 20 customers contributing about 80% of BPM revenue [8][9] - Adjusted operating expenses totaled $16.9 million, up from $14 million in the prior year, largely due to increased stock-based compensation and IPR&D expenses related to the Panthera acquisition [19][16] Market Data and Key Metrics Changes - At the end of Q2, BPM products were embedded in 16 approved therapies and used in over 250 relevant commercially sponsored CGT trials in the U.S., representing over a 70% market share [10] - The company maintains a strong position in late-stage clinical development, with nearly 80% market share in Phase 3 clinical trials [10] Company Strategy and Development Direction - The company is focused on operational execution and disciplined capital allocation, with a sharpened focus on its product portfolio and market share in cell processing [7] - A strategic investment in Pluristics was made to explore product portfolio expansion into relevant adjacencies [12] - The company raised its full-year revenue guidance to $100 million to $103 million, reflecting a growth of 22% to 25% [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macro uncertainties, citing strong visibility from major customers [26] - The FDA's recent decision to remove the REMS requirement is viewed as a positive development for the CGT landscape, potentially enhancing patient access to therapies [13] - The company expects continued strength in cell processing revenue despite broader market uncertainties [7] Other Important Information - The company reported cash and marketable securities of $100.2 million at the end of Q2 2025 [21] - The acquisition of Panthera is expected to enhance market leadership in biopreservation and introduce new product lines [54] Q&A Session Summary Question: Guidance visibility and commercial ramps - Management indicated good visibility into revenue from top customers and expressed confidence in the second half of the year despite potential lumpiness between Q3 and Q4 [26][27] Question: Cross-selling dynamics - Management noted early traction in cross-selling efforts, with larger accounts showing interest in additional products [31] Question: CryoCase timeline - Management is in discussions with a large customer regarding changes to the CryoCase and has over 30 customers evaluating it [35] Question: Pluristics investment and competition - Management does not view Pluristics as a competitive threat but is interested in their assay development capabilities [40] Question: Panthera updates - The company remains on track to have commercial products from Panthera in the market by the second half of next year [42] Question: Demand trends in early clinical stages - Management noted a slight softness in demand from smaller Phase I and II customers but expects overall growth to continue [49] Question: Distribution channel visibility - Management has not seen any weakness in the distribution channel and remains confident in its strength for the remainder of the year [53] Question: M&A strategy - The company emphasizes a disciplined approach to M&A, focusing on strategic rationale and market leadership [60]

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) The financial information for the period ended June 30, 2025, reflects strategic divestitures and an acquisition, impacting revenue, net loss, and cash balances [Item 1. Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) The unaudited condensed consolidated financial statements for the period ended June 30, 2025, reflect significant changes due to strategic divestitures and an acquisition, with revenue growth but a net loss from continuing operations [Unaudited Condensed Consolidated Balance Sheets](index=4&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) Condensed consolidated balance sheet highlights show a decrease in cash and an increase in available-for-sale securities Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $31,902 | $95,386 | | Available-for-sale securities (Total) | $68,335 | $13,826 | | Total current assets | $125,432 | $148,761 | | Goodwill | $212,304 | $212,304 | | Total assets | $387,240 | $399,487 | | **Liabilities & Equity** | | | | Total current liabilities | $28,312 | $32,734 | | Debt, long-term | $0 | $4,997 | | Total liabilities | $40,085 | $50,578 | | Total shareholders' equity | $347,155 | $348,909 | - Cash and cash equivalents significantly decreased from **$95.4 million** at the end of 2024 to **$31.9 million** as of June 30, 2025, while available-for-sale securities increased substantially from **$13.8 million** to **$68.3 million**[9](index=9&type=chunk) [Unaudited Condensed Consolidated Statements of Operations](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) The statements of operations show increased revenue but a significant operating loss due to a one-time IPR&D expense Statement of Operations Summary (in thousands, except per share data) | Metric | Q2 2025 | Q2 2024 | Six Months 2025 | Six Months 2024 | | :--- | :--- | :--- | :--- | :--- | | Total revenue | $25,421 | $19,715 | $49,362 | $38,148 | | Total operating expenses | $42,064 | $21,021 | $67,222 | $42,749 | | IPR&D expense | $15,521 | $0 | $15,521 | $0 | | Operating loss | $(16,643) | $(1,306) | $(17,860) | $(4,601) | | Net loss from continuing operations | $(15,838) | $(5,560) | $(16,286) | $(8,759) | | Loss from discontinued operations | $0 | $(15,159) | $0 | $(22,181) | | Net loss | $(15,838) | $(20,719) | $(16,286) | $(30,940) | | Loss per share (continuing ops) | $(0.33) | $(0.12) | $(0.34) | $(0.19) | - A significant IPR&D expense of **$15.5 million** was recorded in Q2 2025, leading to a substantial increase in operating loss to **$16.6 million** for the quarter, compared to a **$1.3 million** loss in Q2 2024[12](index=12&type=chunk) [Unaudited Condensed Consolidated Statements of Cash Flows](index=12&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash flow statements indicate a net decrease in cash and cash equivalents, primarily driven by investing activities related to acquisitions and securities Cash Flow Summary for the Six Months Ended June 30 (in thousands) | Cash Flow Category | 2025 | 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $9,095 | $1,984 | | Net cash used in investing activities | $(66,709) | $(13,656) | | Net cash used in financing activities | $(5,870) | $(1,656) | | **Net decrease in cash and cash equivalents** | **$(63,484)** | **$(13,328)** | - Investing activities used **$66.7 million** in the first six months of 2025, primarily due to purchases of available-for-sale securities (**$64.3 million**) and an investment in IPR&D (**$10.2 million**) related to the PanTHERA acquisition[30](index=30&type=chunk) - Financing activities used **$5.9 million**, mainly due to **$5.0 million** in payments on term loans[30](index=30&type=chunk) [Notes to Unaudited Condensed Consolidated Financial Statements](index=15&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) The notes detail significant strategic changes, including the PanTHERA acquisition and divestitures of Global Cooling, SciSafe, and CBS - The company has undergone significant strategic changes, including the acquisition of PanTHERA CryoSolutions Inc. on April 4, 2025, and the divestiture of Global Cooling, SciSafe, and CBS, which are now treated as discontinued operations[35](index=35&type=chunk)[36](index=36&type=chunk)[37](index=37&type=chunk)[38](index=38&type=chunk) - The PanTHERA transaction was accounted for as an asset acquisition, with the **$15.5 million** value of its IPR&D technology being expensed immediately as it had no alternative future use[60](index=60&type=chunk)[61](index=61&type=chunk) - The company recorded a net loss on disposal of Global Cooling of **$8.9 million** and CBS of **$3.4 million**, and a net gain on disposal of SciSafe of **$28.1 million**[70](index=70&type=chunk)[77](index=77&type=chunk)[86](index=86&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=45&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes revenue growth to increased customer demand and discusses the impact of the PanTHERA acquisition on expenses, while affirming sufficient liquidity Revenue by Category - Six Months Ended June 30 (in thousands) | Revenue Category | 2025 | 2024 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | **Product revenue** | | | | | | Cell processing | $44,473 | $34,124 | $10,349 | 30% | | evo and Thaw | $1,535 | $731 | $804 | 110% | | **Rental revenue** | | | | | | evo and Thaw | $3,258 | $3,194 | $64 | 2% | | **Total revenue** | **$49,362** | **$38,148** | **$11,214** | **29%** | - The increase in cell processing product revenue was driven by an overall market improvement and increased demand from largest customers after a period of safety stock reduction in the prior year[183](index=183&type=chunk) - Total operating expenses for the six months ended June 30, 2025, increased by **57%** to **$67.2 million**, primarily due to the **$15.5 million** IPR&D expense related to the PanTHERA acquisition[187](index=187&type=chunk)[196](index=196&type=chunk) - The company believes its current cash, cash equivalents, and other liquid assets of **$100.2 million** are sufficient to meet liquidity needs for at least the next twelve months[201](index=201&type=chunk)[206](index=206&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=51&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company's primary market risk is interest rate exposure on investments and debt, managed through high-quality, short-term debt instruments, with no material impact reported - The company's main market risk is interest rate risk related to its marketable securities and long-term debt[213](index=213&type=chunk) - Risk is mitigated by investing in high-quality, short-term debt instruments and having long-term debt that is primarily at a fixed rate with a variable component subject to a ceiling[214](index=214&type=chunk)[215](index=215&type=chunk) - Management asserts that interest rate fluctuations have not materially impacted the financial statements[216](index=216&type=chunk) [Item 4. Controls and Procedures](index=52&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls were effective as of June 30, 2025, having remediated a prior material weakness and implemented new controls for the PanTHERA acquisition - Management concluded that disclosure controls and procedures were effective as of June 30, 2025[217](index=217&type=chunk) - A material weakness in internal control over financial reporting related to stock-based awards, identified as of December 31, 2024, was remediated during the quarter ended March 31, 2025[218](index=218&type=chunk) - New internal controls were implemented related to the acquisition of PanTHERA[219](index=219&type=chunk) [PART II. OTHER INFORMATION](index=53&type=section&id=PART%20II.%20OTHER%20INFORMATION) This section covers other required disclosures, including legal proceedings, risk factors, equity sales, defaults, mine safety, and exhibits [Item 1. Legal Proceedings](index=53&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently aware of any legal proceedings or claims expected to have a material adverse effect on its business or financial condition - The company reports no material legal proceedings[221](index=221&type=chunk) [Item 1A. Risk Factors](index=53&type=section&id=Item%201A.%20Risk%20Factors) There have been no material changes to the risk factors previously disclosed in the company's Annual Report on Form 10-K - No material changes to risk factors have occurred since the last Annual Report[222](index=222&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=53&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities or use of proceeds during the period - None reported[223](index=223&type=chunk) [Item 3. Defaults Upon Senior Securities](index=53&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities - None reported[224](index=224&type=chunk) [Item 4. Mine Safety Disclosures](index=53&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - None reported[225](index=225&type=chunk) [Item 5. Other Information](index=53&type=section&id=Item%205.%20Other%20Information) The company reported no other information required to be disclosed under this item - None reported[226](index=226&type=chunk) [Item 6. Exhibits](index=54&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including CEO and CFO certifications and XBRL interactive data files - The report includes standard CEO/CFO certifications and XBRL data files as exhibits[227](index=227&type=chunk)

[Second Quarter 2025 Financial and Business Overview](index=1&type=section&id=Second%20Quarter%202025%20Financial%20and%20Business%20Overview) The company reported strong Q2 2025 results, driven by cell processing revenue growth and strategic acquisitions, despite a GAAP net loss impacted by a one-time IPR&D expense [Management Commentary and Business Highlights](index=1&type=section&id=Management%20Commentary%20and%20Business%20Highlights) Management reported strong Q2 performance, with cell processing revenue up 28% year-over-year, driven by the biopreservation media franchise and strategic acquisitions - Cell processing revenue increased by **28% year-over-year**, achieving its **seventh consecutive quarter** of sequential growth, primarily led by the biopreservation media (BPM) franchise[4](index=4&type=chunk) - The company's biopreservation media is utilized in **over 250** commercially sponsored clinical trials in the U.S., representing **over 70% market share**, and is embedded in **16 unique commercial cell and gene therapies**[6](index=6&type=chunk) - Strategic growth initiatives included the **acquisition of the remaining 90% of PanTHERA CryoSolutions** to enhance biopreservation capabilities and a **$2.0 million investment in Pluristyx, Inc.** to support iPSC-based product development[10](index=10&type=chunk) [Key Financial Highlights](index=1&type=section&id=Key%20Financial%20Highlights) Q2 2025 saw Cell Processing revenue grow 28% to $23.0 million, with a GAAP net loss of $15.8 million largely due to a $15.5 million IPR&D expense Q2 2025 Key Financial Metrics | Metric | Value | | :--- | :--- | | Cell Processing Revenue | $23.0 million (+28% YoY) | | GAAP Gross Margin | 62% | | Non-GAAP Adj. Gross Margin | 65% | | GAAP Net Loss | $15.8 million | | Non-GAAP Adj. EBITDA | $6.1 million (24% of revenue) | - The GAAP net loss includes a significant one-time, non-cash charge of **$15.5 million** for in-process research and development (IPR&D) from the PanTHERA acquisition, impacting GAAP EPS by approximately **$0.32** for the quarter[1](index=1&type=chunk)[7](index=7&type=chunk) [Second Quarter 2025 Financial Results](index=2&type=section&id=Second%20Quarter%202025%20Financial%20Results) Q2 2025 financial results show significant revenue growth across platforms, improved adjusted profitability, and a solid cash position [Revenue](index=2&type=section&id=Revenue) Total revenue for Q2 2025 increased 29% year-over-year to $25.4 million, driven by strong growth in both Cell Processing and evo and Thaw platforms Revenue Performance (Q2 2025 vs Q2 2024) | Revenue Stream | Q2 2025 (Millions USD) | YoY Growth | | :--- | :--- | :--- | | Total Revenue | $25.4 | 29% | | Cell Processing Platform | $23.0 | 28% | | evo and Thaw Platform | $2.5 | 44% | Revenue Performance (Six Months Ended June 30, 2025 vs 2024) | Revenue Stream | H1 2025 (Millions USD) | YoY Growth | | :--- | :--- | :--- | | Total Revenue | $49.4 | 29% | | Cell Processing Platform | $44.6 | 30% | | evo and Thaw Platform | $4.8 | 22% | [Profitability and Margins](index=3&type=section&id=Profitability%20and%20Margins) Q2 2025 GAAP gross margin was 62%, with a GAAP operating loss of $16.6 million, while adjusted EBITDA improved to $6.1 million, or 24% of revenue Gross Margin Performance (Q2 2025 vs Q2 2024) | Metric | Q2 2025 | Q2 2024 | | :--- | :--- | :--- | | GAAP Gross Margin | 62% | 64% | | Non-GAAP Adj. Gross Margin | 65% | 67% | Profitability Metrics (Q2 2025 vs Q2 2024) | Metric | Q2 2025 (Millions USD) | Q2 2024 (Millions USD) | | :--- | :--- | :--- | | GAAP Operating Loss | ($16.6) | ($1.3) | | GAAP Net Loss | ($15.8) | ($5.6) | | GAAP Loss Per Share | ($0.33) | ($0.12) | | Non-GAAP Adj. Net Income/(Loss) | $0.5 | ($1.0) | - Adjusted EBITDA for Q2 2025 increased to **$6.1 million** (**24% of revenue**) from **$3.9 million** (**20% of revenue**) in Q2 2024, with the six-month adjusted EBITDA at **$11.8 million** (**24% of revenue**), up from **$6.5 million** (**17% of revenue**) in the prior year[16](index=16&type=chunk)[19](index=19&type=chunk) [Financial Position](index=5&type=section&id=Financial%20Position) As of June 30, 2025, the company maintained a strong financial position with $100.2 million in cash, cash equivalents, and marketable securities - The company's cash, cash equivalents, and marketable securities totaled **$100.2 million** as of June 30, 2025[20](index=20&type=chunk) [2025 Financial Guidance](index=1&type=section&id=2025%20Financial%20Guidance) The company raised its full-year 2025 revenue guidance, reflecting strong performance and an optimistic outlook for gross and EBITDA margins [Updated Revenue and Margin Outlook](index=1&type=section&id=Updated%20Revenue%20and%20Margin%20Outlook) BioLife Solutions raised its full-year 2025 revenue guidance to $100.0 - $103.0 million, anticipating GAAP gross margin in the low 60% range Full-Year 2025 Revenue Guidance | Category | Revised Guidance (Millions USD) | Prior Guidance (Millions USD) | YoY Growth | | :--- | :--- | :--- | :--- | | Total Revenue | $100.0 - $103.0 | $95.5 - $99.0 | 22% - 25% | | Cell Processing Revenue | $91.0 - $93.0 | $86.5 - $89.0 | 24% - 26% | | evo and Thaw Revenue | $9.0 - $10.0 | Affirmed | 3% - 15% | - Management expects full-year 2025 GAAP gross margin to be in the **low 60% range** and adjusted gross margin (non-GAAP) in the **mid-60% range**, with continued expansion of adjusted EBITDA margin compared to 2024[20](index=20&type=chunk) [Consolidated Financial Statements (Unaudited)](index=8&type=section&id=Consolidated%20Financial%20Statements%20%28Unaudited%29) This section provides the unaudited consolidated financial statements, including statements of operations, balance sheet, and cash flows for the periods presented [Condensed Consolidated Statements of Operations](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) This section presents the unaudited statements of operations for Q2 and H1 2025, detailing revenue, operating expenses, and net loss from continuing operations Condensed Consolidated Statements of Operations (in thousands) | | Three Months Ended June 30, | Six Months Ended June 30, | | :--- | :--- | :--- | | | **2025** | **2024** | **2025** | **2024** | | **Total revenue** | **$25,421** | **$19,715** | **$49,362** | **$38,148** | | Total operating expenses | $42,064 | $21,021 | $67,222 | $42,749 | | *IPR&D expense* | *$15,521* | *$—* | *$15,521* | *$—* | | **Operating loss** | **($16,643)** | **($1,306)** | **($17,860)** | **($4,601)** | | **Net loss from continuing operations** | **($15,838)** | **($5,560)** | **($16,286)** | **($8,759)** | | **Loss per share from continuing ops** | **($0.33)** | **($0.12)** | **($0.34)** | **($0.19)** | [Condensed Consolidated Balance Sheet](index=10&type=section&id=Condensed%20Consolidated%20Balance%20Sheet) This section provides a snapshot of the company's financial position, comparing assets, liabilities, and equity as of June 30, 2025, and December 31, 2024 Condensed Consolidated Balance Sheet Information (in thousands) | | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash, cash equivalents, and marketable securities | $100,237 | $109,212 | | Total assets | $387,240 | $399,487 | | Total liabilities | $40,085 | $50,578 | | Total shareholders' equity | $347,155 | $348,909 | [Condensed Consolidated Statement of Cash Flows](index=12&type=section&id=Condensed%20Consolidated%20Statement%20of%20Cash%20Flows) This statement details cash flows for the six months ended June 30, 2025, showing positive operating cash flow and a net decrease in cash Condensed Consolidated Statement of Cash Flows (in thousands, for six months ended June 30) | | 2025 | 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $9,095 | $1,984 | | Net cash used in investing activities | ($66,709) | ($13,656) | | Net cash used in financing activities | ($5,870) | ($1,656) | | **Net decrease in cash and cash equivalents** | **($63,484)** | **($13,393)** | [Reconciliation of GAAP to Non-GAAP Financial Measures](index=12&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Financial%20Measures) This section provides detailed reconciliations of GAAP financial measures to their non-GAAP adjusted counterparts, highlighting key adjustments [Reconciliation of Gross Profit and Gross Margin](index=12&type=section&id=Reconciliation%20of%20Gross%20Profit%20and%20Gross%20Margin) This section reconciles GAAP gross profit to non-GAAP adjusted gross profit, showing Q2 2025 GAAP gross margin at 62% and adjusted gross margin at 65% Reconciliation of Gross Profit (in thousands) | | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | | :--- | :--- | :--- | | **GAAP GROSS PROFIT** | **$15,831 (62%)** | **$31,022 (63%)** | | Intangible asset amortization | $602 | $1,198 | | **ADJUSTED GROSS PROFIT** | **$16,433 (65%)** | **$32,208 (65%)** | [Reconciliation of Operating Loss/Income](index=16&type=section&id=Reconciliation%20of%20Operating%20Loss%2FIncome) This table reconciles GAAP operating loss to non-GAAP adjusted operating loss by excluding specific non-recurring and non-cash items Reconciliation of Operating Loss (in thousands) | | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | | :--- | :--- | :--- | | **GAAP OPERATING LOSS** | **($16,643)** | **($17,860)** | | IPR&D expense | $15,521 | $15,521 | | Intangible asset amortization | $708 | $1,410 | | Other adjustments | ($59) | $1,347 | | **ADJUSTED OPERATING (LOSS)/INCOME** | **($473)** | **$418** | [Reconciliation of Net Loss/Income](index=18&type=section&id=Reconciliation%20of%20Net%20Loss%2FIncome) This section reconciles GAAP net loss to non-GAAP adjusted net income by removing the impact of non-recurring or non-cash items Reconciliation of Net Loss (in thousands) | | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | | :--- | :--- | :--- | | **GAAP NET LOSS** | **($15,838)** | **($16,286)** | | IPR&D expense | $15,521 | $15,521 | | Intangible asset amortization | $708 | $1,410 | | Other adjustments | $67 | $1,487 | | **ADJUSTED NET INCOME** | **$458** | **$2,132** | [Reconciliation of Adjusted EBITDA](index=19&type=section&id=Reconciliation%20of%20Adjusted%20EBITDA) This table reconciles GAAP net loss to non-GAAP adjusted EBITDA, incorporating adjustments for non-cash and non-recurring expenses Reconciliation to Adjusted EBITDA (in thousands) | | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 | | :--- | :--- | :--- | | **GAAP NET LOSS** | **($15,838)** | **($16,286)** | | Interest, Taxes, Depreciation & Amortization | $823 | $1,541 | | **EBITDA** | **($15,215)** | **($15,050)** | | Share-based compensation | $5,849 | $10,002 | | IPR&D expense | $15,521 | $15,521 | | Other adjustments | ($59) | $1,347 | | **ADJUSTED EBITDA** | **$6,096 (24% of Revenue)** | **$11,820 (24% of Revenue)** |

Core Insights - BioLife Solutions, Inc. has invested $2 million in convertible notes of Pluristyx, Inc., a Seattle-based developer of iPSC-based products for cell therapy [1] - This investment is part of a larger financing round and includes a board observer seat and rights related to potential future acquisitions of Pluristyx [1] Company Overview - BioLife Solutions specializes in bioproduction products and services for the cell and gene therapy market, facilitating the commercialization of new therapies [4] - Pluristyx focuses on developing next-generation cell-based tools and therapies, offering products like PluriKit™, PluriForm™ Organoids, and PluriBank™ stem cells [3] Strategic Rationale - The investment aligns with BioLife's strategy to explore biological assays as a product portfolio adjacency, following similar investments in other companies [2] - Pluristyx's recent development of an iPSC-based biological assay for organoid manufacturing complements BioLife's interests [2]

Core Insights - BioLife Solutions, Inc. is set to release its second quarter 2025 financial results on August 7, 2025, after market close [1] - A conference call and live webcast will be held at 4:30 PM ET to discuss the financial results and provide a business update [1] Company Overview - BioLife Solutions is a prominent developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market [3] - The company specializes in solutions that preserve the health and function of biological materials throughout their lifecycle, including collection, development, storage, and distribution [3] Investor Relations - Investors can access the webcast through the Investor Relations page on the BioLife Solutions website [2] - The conference call can be joined via toll-free numbers for domestic and international callers [2] - A replay of the webcast will be available approximately two hours after the call and archived for 90 days [2]

Group 1 - BioLife Solutions, Inc. (BLFS) closed at $22.03, with a 3.2% gain over the past four weeks, and a mean price target of $31.22 indicating a 41.7% upside potential [1] - The average of nine short-term price targets ranges from $30 to $34, with a standard deviation of $1.48, suggesting a low variability among analysts [2] - Analysts are optimistic about BLFS's earnings prospects, with a significant increase in the Zacks Consensus Estimate for the current year by 123.1% [12] Group 2 - The Zacks Rank for BLFS is 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - Analysts' agreement on higher earnings estimates is a strong indicator of potential stock price movements, as empirical research shows a correlation between earnings estimate revisions and stock price changes [11] - While price targets are often viewed skeptically, the direction they imply for BLFS appears to be a good guide for potential upside [10][13]

Core Insights - BioLife Solutions, Inc. is a prominent developer and supplier of bioproduction products and services specifically for the cell and gene therapy (CGT) market [1] - The company is actively participating in several upcoming investor conferences, indicating a focus on investor relations and market engagement [3] Company Overview - BioLife Solutions specializes in solutions that preserve the health and functionality of biological materials throughout their lifecycle, including collection, development, storage, and distribution [1] Upcoming Investor Conferences - The company will participate in the following conferences: - 22nd Annual Craig-Hallum Institutional Investor Conference on May 28, 2025, in Minneapolis, MN [3] - Benchmark 2025 Healthcare House Call Virtual Conference on May 29, 2025, virtually [3] - Jefferies Global Life Sciences Conference from June 3 to June 5, 2025, in New York, NY [3] - Wolfe Research Small & Mid-Cap Conference on June 5, 2025, in New York, NY [3] - Northland Growth Conference 2025 on June 25, 2025, virtually [3]